Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Bradford · SciRah

Researcher profile · Semantic Scholar

W. Bradford

Share profile

W. Bradford — researcher profile on SciRah

h-index: 36
Works: 113
Citations: 13K

Most-cited papers

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
T. King, W. Bradford, S. Castro-Bernardini, E. Fagan +13 more
2014New England Journal of Medicine2,139 citations Open access
Semantic Scholar
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
P. Noble, C. Albera, W. Bradford, U. Costabel +8 more
2011The Lancet2,052 citations
Semantic Scholar
Incidence and prevalence of idiopathic pulmonary fibrosis.
G. Raghu, D. Weycker, J. Edelsberg, W. Bradford +1 more
2006American Journal of Respiratory and Critical Care Medicine1,241 citations
Semantic Scholar
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
G. Raghu, K. Brown, W. Bradford, K. Starko +3 more
2004New England Journal of Medicine611 citations Open access
Semantic Scholar
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
F. Martinez, S. Safrin, D. Weycker, K. Starko +7 more
2005Annals of Internal Medicine604 citations
Semantic Scholar
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
T. King, C. Albera, W. Bradford, U. Costabel +8 more
2009The Lancet507 citations Open access
Semantic Scholar
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.
D. Lynch, J. Godwin, S. Safrin, Karen M. Starko +7 more
2005American Journal of Respiratory and Critical Care Medicine504 citations
Semantic Scholar
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
R. D. du Bois, D. Weycker, C. Albera, W. Bradford +9 more
2011American Journal of Respiratory and Critical Care Medicine475 citations Open access
Semantic Scholar
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
R. D. du Bois, D. Weycker, C. Albera, W. Bradford +9 more
2011American Journal of Respiratory and Critical Care Medicine462 citations Open access
Semantic Scholar
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
P. Noble, C. Albera, W. Bradford, U. Costabel +13 more
2016European Respiratory Journal438 citations Open access
Semantic Scholar
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.
R. D. du Bois, D. Weycker, C. Albera, W. Bradford +10 more
2010American Journal of Respiratory and Critical Care Medicine404 citations Open access
Semantic Scholar
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
S. Nathan, C. Albera, W. Bradford, U. Costabel +11 more
2017The Lancet Respiratory Medicine292 citations
Semantic Scholar
Isoniazid, Rifampin, Ethambutol and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis — Botswana
Sekai Chideya, C. Winston, C. Peloquin, W. Bradford +6 more
2009Clinical Infectious Diseases252 citations Open access
Semantic Scholar
6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
R. D. du Bois, C. Albera, W. Bradford, U. Costabel +6 more
2013European Respiratory Journal231 citations Open access
Semantic Scholar
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.
T. Blackwell, A. Tager, Z. Borok, B. Moore +44 more
2014American Journal of Respiratory and Critical Care Medicine225 citations Open access
Semantic Scholar
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
S. Nathan, C. Albera, W. Bradford, U. Costabel +15 more
2016Thorax170 citations Open access
Semantic Scholar
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
J. Tappero, W. Bradford, T. Agerton, P. Hopewell +8 more
2005Clinical Infectious Diseases162 citations
Semantic Scholar
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
T. King, C. Albera, W. Bradford, U. Costabel +6 more
2014American Journal of Respiratory and Critical Care Medicine146 citations Open access
Semantic Scholar
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
L. Lancaster, C. Albera, W. Bradford, U. Costabel +13 more
2016BMJ Open Respiratory Research122 citations Open access
Semantic Scholar
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
D. Alberts, C. Marth, R. Alvarez, G. Johnson +7 more
2008Gynecologic Oncology118 citations
Semantic Scholar
Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection.
T. Araǵon, D. Vugia, S. Shallow, M. Samuel +3 more
2007Clinical Infectious Diseases113 citations
Semantic Scholar
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
S. Nathan, R. D. du Bois, C. Albera, W. Bradford +7 more
2015Respiratory Medicine108 citations Open access
Semantic Scholar
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
D. Valeyre, C. Albera, W. Bradford, U. Costabel +5 more
2014Respirology (Carlton South. Print)105 citations Open access
Semantic Scholar
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.
B. Ley, W. Bradford, E. Vittinghoff, D. Weycker +2 more
2016American Journal of Respiratory and Critical Care Medicine95 citations Open access
Semantic Scholar
The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA.
W. Bradford, Jeffrey N. Martin, A. Reingold, G. Schecter +2 more
1996The Lancet93 citations Open access
Semantic Scholar
Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis
B. Ley, W. Bradford, D. Weycker, E. Vittinghoff +2 more
2015European Respiratory Journal89 citations Open access
Semantic Scholar
HIV infection as a risk factor for shigellosis.
Jefferson T. Baer, D. Vugia, A. Reingold, T. Araǵon +2 more
1999Emerging Infectious Diseases86 citations Open access
Semantic Scholar
Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia
T. Fingerlin, Wei-Ming Zhang, Ivana V. Yang, H. Ainsworth +49 more
2016BMC Genetics83 citations Open access
Semantic Scholar
A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial)
F. Giles, C. Miller, D. Hurd, J. Wingard +9 more
2003Leukemia and Lymphoma77 citations
Semantic Scholar
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
U. Costabel, C. Albera, W. Bradford, P. Hormel +5 more
2012Sarcoidosis Vasculities and Diffuse Lung Diseases68 citations
Semantic Scholar
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
N. Forestier, D. Larrey, D. Guyader, P. Marcellin +8 more
2011Journal of Hepatology66 citations
Semantic Scholar
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.
Robert Brownell, N. Kaminski, P. Woodruff, W. Bradford +3 more
2016American Journal of Respiratory and Critical Care Medicine56 citations Open access
Semantic Scholar
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
H. Collard, W. Bradford, V. Cottin, K. Flaherty +10 more
2015European Respiratory Journal52 citations Open access
Semantic Scholar
Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution
Sharlene R. Lim, X. Qin, S. Susser, J. B. Nicholas +12 more
2011Antimicrobial Agents and Chemotherapy44 citations Open access
Semantic Scholar
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
D. Lederer, W. Bradford, E. Fagan, I. Glaspole +10 more
2015Chest38 citations Open access
Semantic Scholar
SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
R. Corcoran, M. Giannakis, J. Allen, Jonathan H. Chen +18 more
202037 citations Open access
Semantic Scholar
Treatments for idiopathic pulmonary fibrosis.
T. King, P. Noble, W. Bradford
2014New England Journal of Medicine34 citations
Semantic Scholar
Dissemination of Mycobacterium tuberculosis across the San Francisco Bay Area.
W. Bradford, Jane Koehler, H. el-Hajj, P. Hopewell +7 more
1998Journal of Infectious Diseases27 citations
Semantic Scholar
The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study
U. Costabel, C. Albera, Alan H. Cohen, W. Bradford +5 more
2011European Respiratory Journal22 citations
Semantic Scholar
85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV)
N. Forestier, D. Larrey, P. Marcellin, Y. Benhamou +6 more
200921 citations Open access
Semantic Scholar
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
N. Forestier, D. Larrey, P. Marcellin, D. Guyader +9 more
2011Journal of Infectious Diseases20 citations
Semantic Scholar
A computer-assisted molecular epidemiologic approach to confronting the reemergence of tuberculosis.
Gregory B. Woelffer, W. Bradford, A. Paz, P. M. Small
1996American Journal of the Medical Sciences20 citations Open access
Semantic Scholar
Danoprevir Monotherapy Decreases Inflammatory Markers in Patients with Chronic Hepatitis C Virus Infection
C. Schaefer, K. Kossen, Sharlene R. Lim, Jiing-Huey Lin +4 more
2011Antimicrobial Agents and Chemotherapy16 citations Open access
Semantic Scholar
The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF).
P. Noble, C. Albera, W. Bradford, U. Costabel +6 more
2009Asian Test Symposium16 citations
Semantic Scholar
Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis.
W. Bradford, Alan H. Cohen, J. Leff
2013American Journal of Respiratory and Critical Care Medicine15 citations
Semantic Scholar
Rates and Characteristics of Death in Patients With Idiopathic Pulmonary Fibrosis (IPF
F. Martinez, W. Bradford, S. Safrin, K. Starko +1 more
200313 citations
Semantic Scholar
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
T. Fingerlin, Elissa Murphy, Wei-Ming Zhang, A. Peljto +46 more
2013Nature Genetics9 citations Open access
Semantic Scholar
Pirfenidone is Efficacious in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Mild Restrictive Disease
U. Costabel, C. Albera, W. Bradford, E. Fagan +13 more
20168 citations
Semantic Scholar
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials
U. Costabel, L. Lancaster, C. Albera, W. Bradford +12 more
20168 citations
Semantic Scholar
6-Minute Walk Test Distance (6MWD) Is A Reliable, Valid, And Responsive Outcome Measure That Predicts Mortality In Patients With IPF
R. D. du Bois, C. Albera, U. Costabel, W. Bradford +7 more
2010Asian Test Symposium8 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. King×24
Invite
T. King — researcher profile on SciRah
P. Noble×24
Invite
P. Noble — researcher profile on SciRah
R. D. du Bois×20
Invite
R. D. du Bois — researcher profile on SciRah
C. Albera×19
Invite
C. Albera — researcher profile on SciRah

×19

Invite

U. Costabel — researcher profile on SciRah

Invite

D. Valeyre — researcher profile on SciRah

L. Lancaster×15

Invite

L. Lancaster — researcher profile on SciRah

Invite

S. Sahn — researcher profile on SciRah

Invite

S. Nathan — researcher profile on SciRah

Invite

D. Weycker — researcher profile on SciRah

M. Glassberg×9

Invite

M. Glassberg — researcher profile on SciRah

Invite

I. Glaspole — researcher profile on SciRah